SOURCE: ChromoCure, Inc.

March 04, 2010 08:30 ET

ChromoCure Gains More Industry Support as Its Technology Shown Superior to 'Biomarkers': Biomarker Assays Diagnostics "Not Produced Hoped-For Results"

RENO, NV--(Marketwire - March 4, 2010) -  ChromoCure, Inc. (PINKSHEETS: KKUR) -- ChromoCure's role in Cancer Detection and Research received more support from a report of the Cambridge Healthtech Institute's (CHI) "Biomarker Assay Development" conference held in late January in San Diego.

As reported in the March issue of Genetic Engineering & Biotechnology News (Vol. 30, No. 5): "pathway biomarkers have not produced hoped-for results in predicting patients' tumor sensitivity to targeted therapy"... and "[the] technologies also have not lived up to expectations." 

Research has conclusively and irrefutably demonstrated aneuploidy as a more accurate predictor of cancer than cytological/histological analysis or genetic marker-based diagnostics that are the only other methods in existence today. ChromoCure's systems measure aneuploidy as the sole means of detecting cancer presence and measuring cancer progression. The system has a 100% effective accuracy rate.

Biomarkers, when supposedly 'effective,' detect either specific proteins generated by cancer, or a genetic anomaly. BOTH of these effects are products of aneuploidy and BOTH effects are transient due to the evolutionary, ever-changing aspect of aneuploidy. The correlation of 'markers' to the presence of cancer is an effect of the ever-changing chromosomal structures. That's why 'biomarker' approaches are not reliably effective and eventually become completely ineffective. Also of note: the transitional nature of chromosomal imbalance is the reason cancer eventually becomes 'immune' to chemotherapy. The drug targets a certain type of cell configuration. That configuration is momentary in the progression of aneuploidy (cancer). The configuration is also only a PORTION of the population of cells with aneuploidy. Detection of specific aspects of the cancer population is inaccurate and not reliable, as so much was admitted at the CHI conference. Therefore, detection of aneuploidy is 100% effective. It is this unique aspect of cancer present at all stages and in all cancers that is detected by the company's systems.

The Company's proprietary Chromosomal Scanner systems have proven accurate and efficient in the measurement of the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company's detection technology has been proven to have an effective accuracy of 100% for all cancers at all stages. This is superior to biomarker detection in every measurable way. The Company recently published its collaborative clinical testing with a major cancer clinic.

The Company's focus on cancer research is further underscored by recent major clinical publications that both validate ChromoCure's chromosomal/aneuploidy theory of cancer and establish the company's detection approach as the forefront of both cancer detection and research.

The company's technology and related research opens the way for non-invasive and non-toxic solutions to cancer therapeutics and disease eradication. ChromoCure's scanner technologies include proprietary designs, processes, and algorithms centered on chromosomal imbalance. They provide the foundation for significant advantages in delivering important results in diagnosis, therapy and cure.

The Company invites industry and scientific collaboration through its "Project Boveri: Find the Cure" initiative.

About ChromoCure

ChromoCure develops and provides proprietary cancer detection systems and related therapeutic technologies. The Company's proprietary CS200 Chromosomal Scanner has been proven accurate and efficient in the measurement of the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company's detection technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology will become the worldwide gold standard for cancer detection, progression measurement, and research for both therapy and cure. The Company also applies its technology and knowledge to cancer cure and therapeutics research.

Safe-Harbor Statement

This release contains statements or projections regarding future performance that is forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.

Contact Information